Drug Trial Radar · NCT05011305
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis
Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
189
Actual
Start
Aug 18, 2021
Primary completion
Sep 12, 2025
Study completion Sep 12, 2025
Sponsor
- Lead sponsor
- Zydus Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis
Conditions
- Nonalcoholic Steatohepatitis
- Fibrosis
Interventions
Saroglitazar Magnesium 2 mgDrug
Patients randomly assigned to this group will receive Saroglitazar Magnesium 2 mg tablet orally once daily in the morning before breakfast without food, for the duration of treatment.
Saroglitazar Magnesium 4 mgDrug
Patients randomly assigned to this group will receive Saroglitazar Magnesium 4 mg tablet orally once daily in the morning before breakfast without food, for the duration of treatment.
PlaceboDrug
Patients randomly assigned to this group will receive Placebo tablet orally once daily in the morning before breakfast without food, for the duration of treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Resolution of steatohepatitis with no worsening of fibrosisTime frame: 52 Weeks/EOT
Locations
129 sites in 4 countries. Site status is shown where the registry gives one.
Zydus US032
Birmingham, Alabama
Zydus US079
Homewood, Alabama
Zydus US047
Phoenix, Arizona
Zydus US025
Tucson, Arizona
Zydus US087
Tucson, Arizona
Zydus US029
Tucson, Arizona
Zydus US118
Chula Vista, California
Zydus US041
Fresno, California
Zydus US111
Gardena, California
Zydus US013
Huntington Park, California
Zydus US065
La Jolla, California
Zydus US094
Lancaster, California
Zydus US080
Long Beach, California
Zydus US090
Long Beach, California
Zydus US022
Los Angeles, California
Zydus US062
Los Angeles, California
Zydus US023
Murrieta, California
Zydus US052
Orange, California
Zydus US012
Panorama City, California
Zydus US039
Aurora, Colorado
Zydus US122
Clearwater, Florida
Zydus US057
Fort Myers, Florida
Zydus US108
Hallandale, Florida
Zydus US096
Hialeah Gardens, Florida
Zydus US003
Lakeland, Florida
Zydus US016
Lakewood Rch, Florida
Zydus US125
Largo, Florida
Zydus US001
Maitland, Florida
Zydus US124
Maitland, Florida
Zydus US007
Miami, Florida
Zydus US024
Miami, Florida
Zydus US034
Miami, Florida
Zydus US038
Miami, Florida
Zydus US121
Miami, Florida
Zydus US054
Miami, Florida
Zydus US098
Miami Lakes, Florida
Zydus US099
Naples, Florida
Zydus US081
Ocala, Florida
Zydus US085
Orlando, Florida
Zydus US104
Port Orange, Florida
Showing 40 of 129 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.